AI in Drug Discovery Doesn't Need a Perfect Biology Simulator to Reshape the Industry

kenbwork · x · 2026-08-05

This thread discusses the practical application of AI in biopharma and the discourse around the 'verifiability of biology.' The author points out that the industry often falls into the trap of believing perfect biological simulation is a prerequisite for value.

Key Insights:

Imperfection is still useful: Long before we can faithfully predict biological outcomes, AI can accelerate science by constructing rewards for intermediate capabilities.
Focus on data analysis: In biopharma, AI agents that reliably match top-percentile human judgment in data analysis and interpretation will materially drive scientific progress.
Reshaping R&D: A 'country of scientists in a datacenter' wouldn't need a flawless biology simulator to completely reshape how drug programs are designed, staffed, and executed, let alone to have a substantial impact on economic growth.

Original post →

AI in Drug Discovery Doesn't Need a Perfect Biology Simulator to Reshape the Industry

More from AGI Musings